464-ADAM12: A new Checkpoint impeding Anti-Tumor Immunity
This research identifies ADAM12 as a critical molecular checkpoint in cancer-associated fibroblasts (CAFs) that actively prevents the immune system from attacking tumors. Using advanced CRISPR-based single-cell screening on patient tissues, scientists discovered that ADAM12 maintains a pro-tumor environment by fueling TGF-β signaling and suppressing beneficial interferon responses. When ADAM12 is removed, fibroblasts shift from a restrictive "cold" state to a progenitor-like state that permits CD8+ T cell infiltration. This cellular reprogramming successfully shrinks tumors and significantly…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.